206 related articles for article (PubMed ID: 34533854)
1. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect.
Yu H; Wang H; Qie A; Wang J; Liu Y; Gu G; Yang J; Zhang H; Pan W; Tian Z; Wang C
Cancer Sci; 2021 Nov; 112(11):4655-4668. PubMed ID: 34533854
[TBL] [Abstract][Full Text] [Related]
2. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.
Okada T; Murata K; Hirose R; Matsuda C; Komatsu T; Ikekita M; Nakawatari M; Nakayama F; Wakatsuki M; Ohno T; Kato S; Imai T; Imamura T
Sci Rep; 2013 Oct; 3():2899. PubMed ID: 24113164
[TBL] [Abstract][Full Text] [Related]
3. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
[TBL] [Abstract][Full Text] [Related]
4. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
5. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
[TBL] [Abstract][Full Text] [Related]
7. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
Ivy KD; Kaplan JH
Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
[TBL] [Abstract][Full Text] [Related]
8. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
9. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Song L; Li Y; Li W; Wu S; Li Z
J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
11. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
[TBL] [Abstract][Full Text] [Related]
12. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.
Liang ZD; Long Y; Chen HH; Savaraj N; Kuo MT
J Biol Inorg Chem; 2014 Jan; 19(1):17-27. PubMed ID: 24132751
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
16. Overcoming platinum drug resistance with copper-lowering agents.
Chen HH; Kuo MT
Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
[TBL] [Abstract][Full Text] [Related]
17. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
19. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.
Kuo MT; Fu S; Savaraj N; Chen HH
Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]